SCHEDULE: Fortress Biotech Boosts Avenue Therapeutics Stake to 13.4%

Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% following an annual equity grant.

Summary

• Fortress Biotech, Inc. (Reporting Person) filed an Amendment No. 8 to its Schedule 13D regarding its holdings in Avenue Therapeutics, Inc. (Issuer).
• The Reporting Person now beneficially owns 439,955 shares of the Issuer's common stock, representing 13.4% of the outstanding class.
• This ownership includes 250,000 shares of Class A preferred stock, which are convertible into 222 shares of common stock and grant Fortress Biotech a voting majority.
• The Class A preferred stock also entitles Fortress Biotech to annual PIK Dividends in common stock, equal to 2.5% of the Issuer's fully-diluted outstanding capitalization.
• The filing was triggered by the issuance of 111,209 shares of common stock to Fortress Biotech as an Annual Equity Grant under a Founders Agreement.
• Fortress Biotech also holds warrants for 296 shares of common stock, exercisable until July 15, 2035, with an exercise price of $492.75 per share.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is largely procedural, reporting an expected increase in beneficial ownership by a key investor. The continued control and ongoing equity grants by Fortress Biotech are positive for stability, but the very high warrant exercise price could be seen as a historical negative indicator for Avenue Therapeutics' stock performance.

Positives

• Fortress Biotech maintains a significant strategic stake and voting control in Avenue Therapeutics through its Class A preferred stock, ensuring influence over the Issuer's direction.
• The annual equity grant and PIK dividends provide a mechanism for Fortress Biotech to continuously increase its ownership percentage or maintain its proportional stake in Avenue Therapeutics.

Negatives

• The high exercise price of $492.75 for the 296 warrants suggests they are significantly out-of-the-money, potentially indicating a substantial decline in the Issuer's stock value since their issuance.

Risks

• The Class A preferred stock's superior voting rights (1.1 times the common stock equivalent) mean Fortress Biotech will at all times constitute a voting majority, potentially limiting the influence of other common shareholders.

Future Outlook

The filing indicates an ongoing arrangement where Fortress Biotech will continue to receive annual equity grants equal to 2.5% of Avenue Therapeutics' fully-diluted outstanding capitalization and PIK Dividends on its Class A preferred stock, ensuring its continued influence and potential increase in ownership.

Management Comments

• Sole Voting Power includes 296 shares of Issuer's common stock underlying Warrants and 250,000 shares of the Issuer's Class A preferred stock.
• The Issuer's Class A preferred stock is identical to its common stock other than as to voting rights, conversion rights and the PIK Dividend rights.
• The Class A preferred stock will at all times constitute a voting majority.

Industry Context

This filing reflects a common strategy in the biotechnology and pharmaceutical sectors where a founding or significant investor (Fortress Biotech) maintains substantial control and a long-term stake in a spin-off or portfolio company (Avenue Therapeutics) through structured equity arrangements, including preferred stock with superior voting rights and ongoing equity grants. This ensures strategic alignment and continued support from the parent/major investor.

Comparison to Industry Standards

• The use of Class A preferred stock with superior voting rights is a common mechanism for parent companies or significant investors to retain control over a subsidiary or spin-off, similar to dual-class share structures seen in tech companies (e.g., Google/Alphabet, Meta) or other controlled entities.
• Annual equity grants tied to a percentage of fully-diluted capitalization are a standard way for founding entities to maintain their proportional ownership or increase it over time, especially in early-stage or growth-oriented biotech companies where capital raises can dilute other shareholders.
• The high warrant exercise price of $492.75, compared to typical biotech stock prices, suggests a significant historical valuation or a highly dilutive event has occurred, which is not uncommon in the volatile biotech industry where clinical trial results or regulatory approvals can drastically alter valuations.

Corporate Governance

Related Party Transactions

• The Annual Equity Grant of 111,209 shares of common stock to Fortress Biotech, Inc. under the Founders Agreement.
• The Class A preferred stock held by Fortress Biotech, Inc. which provides superior voting rights and PIK Dividends.
• Warrants for 296 shares of common stock issued by Fortress Biotech to its Chairman, President and CEO (Lindsay A. Rosenwald, M.D.) and Executive Vice Chairman (Michael S. Weiss) under a long-term incentive plan.

Stakeholder Impact

• Shareholders (Common): Potential for dilution due to annual equity grants and PIK dividends to Fortress Biotech. Limited influence on corporate governance due to Fortress Biotech's voting majority via Class A preferred stock.
• Fortress Biotech (as a shareholder): Increased ownership stake and continued strong control over Avenue Therapeutics.

Next Steps

• Fortress Biotech will continue to receive PIK Dividends on its Class A preferred stock on each January 1 until conversion or redemption.
• Fortress Biotech will continue to receive annual equity grants equal to 2.5% of Avenue Therapeutics' fully-diluted outstanding equity.
• The Warrants held by Fortress Biotech's executives are exercisable until July 15, 2035.

Key Dates

Recommendation

This filing is an amendment to a Schedule 13D, primarily reporting a routine annual equity grant to Fortress Biotech, Inc. and clarifying its beneficial ownership and control mechanisms in Avenue Therapeutics, Inc. It does not contain new financial performance data, strategic shifts, or unexpected events that would warrant a change in investment thesis. Fortress Biotech's continued significant stake and voting control provide a degree of stability, but the high warrant exercise price suggests past underperformance. Without further operational or financial updates from Avenue Therapeutics, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive news.

Keywords

Fortress Biotech, Avenue Therapeutics, Schedule 13D, Beneficial Ownership, Equity Grant, Preferred Stock, Voting Control, Biotechnology, Pharmaceuticals, SEC Filing